horse serum (HS). L6E9 were then maintained for 4 days and C2C12 for 10 days in these conditions of culture to acquire myotube morphology. Total RNA was extracted from cultured L6E9 or C2C12 cells by using Tripure Isolation Reagent (Boehringer) and 20 µg of total RNA was loaded. Ethidium bromide staining was used to confirm equal loading of RNA. Northern blot analyses were performed using standard methods. Blots were hybridized with full-length rat UCP-3 cDNA (1). Autoradiographs were quantified by densitometric scanning (LKB Instruments).
Polymerase chain reaction amplification of human UCP-3 gene promoter
A fragment of the human UCP-3 gene was amplified by PCR using 200 ng of human genomic DNA. The complementary (3') primer corresponded to bases from +47 to +24 downstream the transcription start site, according to Schrauwen et al. (24) and GenBank/EMBL data (Accession# AF032871). The complementary (5') primer corresponded to -2903 to -2872. The 3' and 5' complementary primers included six base pair noncomplementary extensions capable of generating SmaI and XhoI restriction sites. Reaction was performed in a 50 µl final volume containing 25 pm of each primer, 1.5 mM each dNTP, 10 mM MgCl 2 , and 4 units of Taq DNA polymerase. Thirty cycles were performed at 92ºC for 30 sec, 58ºC for 1 min, and 72ºC for 3 min. The resulting DNA product of ~3 kb was purified, digested with XhoI and SmaI, and cloned in pGL3-basic plasmid (Promega) (opened by BglII, blunt-ended and digested by XhoI), which contains the cDNA for firefly (Photinus pyralis) luciferase as a reporter gene. The whole fragment was sequenced by the dideoxy method using flanking and internal synthetic oligonucleotides. The sequence for the cloned human UCP-3 gene fragment from -2903 to +47 was identical to that previously shown in the GenBank/EMBL data base (Accession #AF032871) and differed from that in ref 25 by the presence of the C to T polymorphism in the proximal region of the promoter, 6 bp upstream the putative TATA box (24) .
Plasmid constructions
The insertion of the fragment from -2903 to +47 of the human UCP-3 gene into pGL3-basic generates -2903hUCP3-Luc. Plasmids containing 5' deletion mutants of this hUCP3-Luc were generated by restriction enzymes. A SacI restriction and religation generates the -588hUCP3-Luc construct. A further deletion was generated from this last construct by restriction with SacI and BglII, blunt ending and religation, thus generating -165hUCP3-Luc.
Point mutation constructs were generated using a Quick-change site-directed mutagenesis kit (Stratagene). In summary, two complementary oligonucleotides containing the desired mutations, flanked by unmodified nucleotide sequence, were synthesized. Of each oligonucleotide, 125 ng and 50 ng of double stranded -165hUCP3-Luc were incubated with 2.5 units of PfuTurbo DNA polymerase. PCR reaction was done for 17 cycles at 95ºC for 30 sec, 55ºC for 1 min, and 68ºC for 14 min. Then, 10 units of DpnI restriction enzyme was added to each PCR reaction and incubated at 37ºC for at least 1 h to digest parental DNA. One microliter of the DpnI-treated DNA was then transformed. To generate the mutations, the oligonucleotides used were: for the E box mutation (-165muthUCP3-Luc) 5' GCCAGCCTCTTGTCCATGG ATCAGGCTGTC 3' (introducing NcoI restriction site); for mut1 (mut1hUCP3-Luc), 5' GGATAAGGTTTCATATGAGCCCGTGTGTATAAGACCA GTGCC 3' (introducing a NdeI restriction site); for mut2 (mut2hUCP3-Luc), 5' CCAACTTCTCTAGGATAAAC GTTCAGGTCAGCCCGTGTG 3' (introducing AclI restriction site). The plasmid -61hUCP3-Luc was generated from mut1hUCP3-Luc by digestion with KpnI and NdeI, blunt-ending, and ligation.
DNA transfection and determination of luciferase activity
Transfection experiments were carried out in L6E9 cells at 50% confluence by using FuGene6 Transfection Reagent (Boehringer) and were performed according to manufacturer's instructions. Each transfection point was done in triplicate in a 6-well plate and contained 1.5 µg of luciferase reporter vector, 0.2 µg of MyoD, pRSV-RARα or pRSV-RXRα expression vectors, and 3 ng of pRL-CMV, an expression vector for the sea pansy (Renilla reniformis) luciferase used as an internal transfection control. Cells were incubated for 48 h after transfection and treated with or without 2 µM all-trans RA or 2 µM 9-cis RA for 24 h before harvest. Firefly luciferase and Renilla luciferase activities were measured in a luminometer using the Dual Luciferase Reporter assay system kit (Promega). Cells were lysed in a 500 µl of PLB (passive lysis buffer) in agitation for 15 min and 20 µl was used for measurement. Luciferase activity elicited by UCP-3 promoter constructs was normalized for variation in transfection efficiency using Renilla luciferase as an internal standard.
Electrophoretic mobility shift assays
Nuclear protein extracts from L6E9 muscle cells were isolated as reported previously (26) , and protein concentration was determined by the micromethod of Bio-Rad (Richmond, CA) using BSA as standard. For gel retardation assays, the double-stranded UCP3-DR1 oligonucleotide corresponding to the -79 to -57 sequence of the UCP-3 gene was end-labeled using [α 32 P]dCTP and klenow enzyme. The DNA probe (25.000 cpm) was incubated for 30 min at 25ºC with 5 µg of L6E9 nuclear protein extract. Reactions were carried out in a final volume of 25 µl containing 20 mM Hepes (pH 7.6), 0.1 mM EDTA, 1 mM dithiothreitol, 50 mM NaCl, 10% glycerol, and 0.5 µg of poly dI.dC (deoxyinosinic-deoxycytidylic acid). Samples were analyzed by electrophoresis at 4ºC for 60-80 min in nondenaturing 5% polyacrylamide gels in 0.5X TBE. In the competition experiments, 100-fold molar excess of unlabeled double-stranded oligonucleotides was included in each respective binding reaction. RARE1 and RARE2 are 24-base pair double-stranded oligonucleotides corresponding to the DR5 RA responsive element in the RARβ gene (27) and to the DR2 RA responsive element in the mouse cellular retinol-binding protein type I gene (28) , respectively. ETS is an oligonucleotide corresponding to the GA-rich region in the stromelysin promoter used as negative control (29) . When indicated, 2 µl of antisera against RARα (C20), RXRα (D20) or ETS (C275) (Santa Cruz) was added to the incubation media for 15 min.
Statistical analysis
Where appropriate, statistical analysis was performed by Student's t test; significance is indicated in the text.
RESULTS

Retinoic acid induces UCP-3 mRNA expression in differentiated C2C12 and L6E9 muscle cells
Northern blot analysis revealed that neither C2C12 nor L6E9 (mouse and rat muscle cell lines) expressed detectable levels of UCP-3 mRNA in the myoblastic stage (Fig. 1A, B) . Nevertheless, when cells were differentiated and acquired a myotube phenotype, low but detectable levels of UCP-3 mRNA were present. As C2C12 need longer time of culture than L6E9 cells to acquire myotube morphology, detectable levels of UCP-3 mRNA appeared later. When the cells were nondifferentiated, treatment with all-trans RA had no effect on UCP-3 expression. However, treatment of myotubes with all-trans RA induced UCP-3 mRNA expression by 8-to tenfold over basal levels in both cell types (Fig. 1A, B) . UCP-3 mRNA levels in differentiated cells after RA treatment were 87 (±15% of those in mouse gastrocnemius muscle. 9-cis RA was added to 4-day differentiated L6E9 cells and induction of UCP-3 mRNA expression was ~50% of the induction observed with all-trans RA (Fig. 1C) . Therefore, expression of UCP-3 mRNA in C2C12 and L6E9 is inducible by RA only when they are differentiated.
Retinoic acid activates the expression of the human UCP-3 gene promoter in L6E9 cellsMyoD is required for the basal promoter activity and RA responsiveness.
We have cloned and sequenced a 3-kb fragment of the human UCP-3 promoter, and this was fused to luciferase reporter gene to study its regulation. The promoter-reporter constructs2903hUCP3-Luc and -1588hUCP3-Luc were used in transient transfection studies in L6E9 cells to identify the fragment of the promoter that contained the elements necessary for expression in muscle cells. Results with both constructs showed low basal luciferase activity. This indicated that either some regulatory elements could be absent in the 3-kb fragment upstream of transcription start site of the UCP-3 gene or that the UCP-3 gene promoter is poorly expressed in these cells because they are myoblasts. This last possibility would be in agreement with the undetectable levels of expression of UCP-3 mRNA in myoblasts shown before. To test the hypothesis that a myogenic factor could be involved in UCP-3 promoter regulation, we cotransfected the -2903hUCP3-Luc and -1588hUCP3-Luc with the MyoD expression plasmid and a 7-and 10-fold induction of the activity over the basal values was obtained respectively (Fig. 2 and data not shown). In contrast, no effect was observed when an expression vector for Mef2C, a myogenic factor from the MADS family, was co-transfected.
To analyze the role of retinoids in UCP-3 promoter activity, co-transfection experiments with expression vectors for RAR and RXR were performed. Results showed that when -1588hUCP3-Luc was transfected in the absence of co-transfected MyoD, no significant differences over the basal level were obtained either by co-transfection with RARα or RXRα alone or together, or by the addition of their agonists, all-trans RA or 9-cis RA. When MyoD was co-transfected, RA caused a significant induction of the promoter. Furthermore, when a RARα expression vector was co-transfected, induction by all-trans RA was much higher. In fact, co-transfection of MyoD plus RARα and treatment with all-trans RA caused ~70-fold induction of the UCP-3 promoter respect to basal activity (Fig. 2) . In contrast, exposure to 9-cis RA in the presence of cotransfected RXRα had no significant effect on UCP-3 promoter activity. Experiments performed with both types of receptor together showed a higher induction as a result of co-transfection, which was significantly increased by exposure to all-trans RA (Fig. 2) . Similar results were obtained with the -2903hUCP3-Luc construct (data not shown). All these results together indicate that MyoD is essential for the activity of the human UCP-3 gene promoter and for RA responsiveness, which is mediated mostly by RAR.
Deletion analysis of the human UCP-3 promoter reveals a RA responsive element in the proximal promoter region
To search for regulatory elements responsible for the effects of RA on the hUCP3 promoter, a set of deletion mutants was created. A major deletion that contained only the proximal 5' region of the gene, -165hUCP3-Luc, retained the same basal activity as the -1588hUCP3-Luc (data not shown) and was activated 8-fold by MyoD. All-trans RA in the presence of co-transfected MyoD and RARα induced 30-fold the activity of -165hUCP3-Luc (Fig. 3) . Moreover, it significantly raised the expression of the construct respect to the MyoD plus RARα−cotransfected in the absence of added ligand. This activation depended on the presence of MyoD (data not shown). Although the level of induction by RA treatment in the -165hUCP3-Luc was somewhat lower than in -1588hUCP3-Luc and, therefore, it was not possible to rule out the presence of RA-responsive elements upstream of -165, it appeared that this proximal fragment should contain the regulatory elements responsible for MyoD and RA action.
Searching for consensus regulatory sequences within this -165 region of the human UCP-3 promoter, an Ebox sequence and one direct repeat (DR1)-like element were located (from -106 to -101 and from -71 to -59, respectively) close upstream from the putative TATA box. A point mutation in the Ebox (-165muthUCP3-Luc), known to disrupt binding of b-HLH proteins (30, 31) , was performed, and no differences were observed regarding MyoD or RA-dependent activation when compared with the wild-type construct. An additional deletion mutant, -61hUCP3-Luc, which lacks both putative sites (Ebox and DR1), still responded to MyoD. Nevertheless, no induction was observed after RA treatment (Fig. 3) , indicating that elements for RA responsiveness are present in the human UCP-3 promoter region between -165 and -61 and are distinct to those mediating MyoD-dependent activity of the promoter.
Point mutation analysis identifies a RARE element in the DR1-like sequence of the proximal UCP-3 gene promoter region
To identify sites responsible for RA action, two different point mutations in the DR1-like element were generated on the -165hUCP3-Luc as described in Methods. As expected, transfection experiments revealed that none of these mutations affect the ability of MyoD to activate the expression of the gene (data not shown). In the presence of MyoD and RARα, mut1UCP3-Luc lost ~80% of the induction by all-trans RA when compared with -165hUCP3-Luc, whereas mut2UCP3-Luc lost ~75% (Fig. 4B) . Mutation of both sites in the same construct (mut1/mut2hUCP3-Luc) abolished the activation of the promoter by RA, demonstrating the involvement of these sites in the regulation of hUCP3 promoter by all-trans RA. To explore the possible presence of additional RA-responsive elements upstream -165, the same point-mutation analysis was performed on the -1588hUCP3-Luc constructs (Fig. 4C) . Results were basically identical to those with the -165hUCP3-Luc: either mutation of the site 1 or of the site 2 suppressed most of RA responsiveness, and mutation of both sites abolished it. These results established that RA responsiveness in the UCP-3 gene promoter is mediated by the DR1 proximal element.
The DR1-like region in the human UCP-3 gene binds RAR and RXR from L6E9 nuclear extracts
To search for the proteins that bind the RA-responsive DR1-like sequence, we performed electrophoretic mobility shift assays with L6E9 nuclei extracts. We used the UCP3-DR1 oligonucleotide, corresponding to the -79/-57 region of the UCP-3 gene, as a labeled probe (Fig.  5C) . A characteristic pattern of DNA-protein binding complexes was formed, as shown in Figure  5A . Four retarded bands appeared: A1, A2, B, and NS. The appearance of A1 and A2 as separate bands was evident only in long electrophoretic runs (Fig. 5B) . Competition assays using the nonlabeled UCP3-DR1 probe revealed that the NS band is nonspecific, because unlabeled oligonucleotide could not compete for the complex. The other bands, A1, A2, and B, were specific because they disappeared in these conditions. The B band disappeared when either DR5-RARE1 (27) or DR2-RARE2 (28) was added to the incubation buffer. An excess of an unlabeled unrelated oligonucleotide (the GA-rich sequence from the stromelysin ETS binding site; see Methods) was used as a negative control and, as expected, no competition effect was detected.
The effects of including specific antibodies against RARα, RXRα, or ETS in the electrophoretic mobility shift assays were determined to confirm the identity of the proteins forming the specific retarded complexes (Fig. 5B) . The presence of RARα antibody in the incubation media prevented the formation of the retarded band B. A partial reduction in the intensity of the band B was also observed when RXRα antibody was present in the assay. In addition, RXRα antibody prevented the formation of bands A1 and A2, whereas the ETS antibody did not affect the pattern of retarded bands. Therefore, we conclude that band B is formed by a complex containing RAR and RXR, whereas band A contains RXR but not RAR.
Competition analysis with an excess of unlabeled oligonucleotides that carry the mutations assayed in the functional promoter analysis (UCP3-DR1m1 and UCP3-DR1m2, shown in Figure  5C ) were performed to identify the sites involved in the DNA-protein binding (Fig. 5C ). The unlabeled UCP3-DR1m1 oligonucleotide competed for proteins that form the complexes A1 and A2, thus preventing the formation of these two bands. The UCP3-DR1m2 oligonucleotide competed for the formation of the RAR-containing complex leading to band B. The oligonucleotide UCP3-DR1m3, which carries a mutation outside the putative RARE element, had no competition effect for the formation of any of the bands. Thus, this result strongly indicates that site 1 is the major site required for binding RAR/RXR complexes, whereas site 2 is also involved in the formation of other RXR-binding complexes that do not include RAR.
DISCUSSION
Here we have established that the UCP-3 gene is expressed in cultured muscle cells only when differentiated. This agrees with the late appearance of UCP-3 gene expression during skeletal muscle ontogeny (11) and indicates that the UCP-3 gene could be considered as a maker of the differentiated stage of muscle cells. Moreover, RA has been identified as a powerful stimulator of UCP-3 gene expression, although the expression of the UCP-3 gene was sensitive to RA only when cells were in the myotube stage. This is similar to the recent report (32) describing a positive effect of 9-cis RA on UCP-3 mRNA in myotubes. These findings are consistent with the behavior of the human UCP-3 gene promoter when transfected into myoblasts. Basal expression of the promoter was negligible and there was no sensitivity to RA. However, MyoD conferred to the UCP-3 gene promoter a substantial expression as well as sensitivity to RA. MyoD is a master regulator of the differentiation program of muscle cell (23) , and the requirement of the UCP-3 gene promoter for MyoD may be responsible for the preferential expression of the gene in differentiated muscle cells and its skeletal muscle-specifc expression in vivo.
The finding that RAR enhanced the responsiveness of the UCP-3 gene promoter to all-trans RA, whereas RXR and 9-cis RA were much less effective, indicates the presence of a RARE in the UCP-3 gene. In most of the RA-responsive genes studied so far RXR has an auxiliary role of providing the heterodimerization partner for RAR (15) , and we observed that co-transfection of RAR plus RXR was maximally effective in inducing the UCP-3 gene promoter. Although ligand-dependent activation of RXR, as a partner of either RAR or other nuclear receptors, cannot be excluded, transfection experiments indicated a major involvement for RAR in mediating responsiveness to RA.
Our results show that a major RARE of the human UCP-3 gene is placed in the proximal promoter region, between -71 and -59. It consists of a DR1-like motif containing an AGGTCA sequence separated by one base pair from another imperfect half site, and the whole sequence is identical in the UCP-3 gene promoter from mouse (33) . This DR1 element was required for RA responsiveness, and it bound a nuclear protein complex from L6E9 muscle cells that contain RAR and RXR. A DR1, which is a 1-bp-separated alignment of direct repeats, has been observed as a characteristic alignment of several RAREs (34, 35) , although it is a less frequent mediator of RAR-dependent responsiveness than other structures of RAREs such as DR5 or DR2 (15) . However, in contrast to these last alignments, which are very restrictive for binding RAR/RXR heterodimers, DR1 elements are highly promiscuous in binding, and they can mediate biological responsiveness to other RXR-containing heterodimers, such as PPAR/RXR, RXR homodimers, and HNF-4 or COUP-TF (36) . Subtle differences in the half-site and flanking sequences of DR1 and promoter context have been reported to mediate preferential binding or responsiveness to different members of the nuclear receptor superfamily (37, 38) . We have observed that the DR1 sequence in the UCP-3 promoter, in addition to RAR/RXR, also binds other RXR-containing complexes from cell muscle nuclei. The expression of the UCP-3 gene is sensitive in vivo to several hormonal signals other than RA that also act through nuclear receptors, as for instance fatty acid derivatives (via PPARs) (11) or thyroid hormones (via thyroid hormone receptors) (7) . Further research will be needed to establish whether the UCP-3 gene promoter is sensitive to activation by other ligands and whether the DR1 RARE identified here acts as a multihormonal cis-acting element in the UCP-3 gene.
Recent evidence has shown that RAR and RXR may functionally and physically interact with MyoD when bound to DNA (22) . The requirement of MyoD for UCP-3 gene promoter activity in response to RA could be compatible with such an interaction. However, the presence of deletion and point-mutation constructs that are responsive to MyoD but unresponsive to RA indicated that the RARE in the UCP-3 gene promoter is distinct and physically separated in the DNA from the cis-acting elements eliciting MyoD action. Mapping the precise site for MyoD action in the UCP-3 gene promoter is beyond the scope of the present study, but it appears that MyoD acts through the minimal promoter region of the UCP-3 gene, in the absence of a conventional E-box binding element. This is similar to the E-box independent action of MyoD on the myosine heavy chain IIB promoter, another skeletal muscle-specific gene, in which MyoD activates gene expression by interaction with the basal transcription machinery (39) . Such a mechanism, if confirmed, would provide a consistent explanation for the dramatic requirement of UCP-3 promoter activity, basal or RA-stimulated, for MyoD.
In summary, RA action constitutes a novel pathway of regulation of UCP-3 gene expression that, in addition to MyoD action, may be critical for the differentiation and development-dependent regulation of the UCP-3 gene expression in skeletal muscle. In 1995, RA was identified as a major inducer of the expression of the UCP-1 gene, as powerful as the classical noradrenergic pathway of regulation of this gene (40) , although the exact physiological meaning of this effect has not been established yet. Recently, we described that 9-cis RA is a major hormonal regulator of UCP-2 gene expression in brown adipocytes (41) , and here we show that transcription of UCP-3 is extremely sensitive to RA. The three UCP proteins are known to uncouple oxidative phosphorylation, and, although their respective physiological functions in relation to thermogenesis and mitochondrial metabolism appear to be distinct, it is remarkable that they are all highly sensitive to retinoids. This may be added to the recent observation that the uncoupling activities of at least UCP1 and UCP2 are affected directly by RA (42) . Recent evidence from studies on transgenic mice bearing a targeted disruption of the UCP-3 gene suggests that UCP-3 may be involved in the regulation of reactive oxygen species production rather than nonshivering thermogenesis (13) . Vitamin A derivatives are essential for the development and differentiation of several tissues, including skeletal muscle, during ontogeny, and for the regular physiological functions of most cell types in the adult. Further research will be needed to define the physiological significance of the action of RA on the expression of UCP-3 gene reported here and, in general, on the function of UCP-3 as part of the mitochondrial energy-producing machinery. -cis RA for 24h. The -1588hUCP3-driven luciferase activity levels were standarized to pRL-CMV-driven Renilla luciferase as transfection internal control. The basal activity of the1588hUCP3-Luc plasmid alone was set to 1. Means ± SE of at least three independent triplicate experiments are shown. Statistically significant differences (p < 0.05) due to the co -transfection with MyoD for each experimental group are shown by * , and those due to the presence of a ligand (all-trans RA or 9-cis RA) respect to its control are shown by ∆. Effects of a point-mutation in the proximal E-box sequence. L6E9 cells were co -transfected with the luciferase reporter constructs depicted on the left and either with or without MyoD plus or minus RAR α expression vectors. The boxes indicate the position of an E -box sequence (-106/-101) and DR1-like element (-71/-59). Following transfection, the cells were cultured for 48h in presence or absence of 2 µM all-trans RA for 24h. The luciferase activity leve ls were standarized to pRL -CMV-driven Renilla luciferase as transfection internal control. The basal activity of the -1588hUCP3-Luc plasmid alone was set to 1. Means ± SE of at least three independent triplicate experiments are shown. Statistically significant differences (p < 0.05) due to the cotransfection with MyoD for each experimental group are shown by * , and those due to the presence of all-trans RA respect to its control are shown by ∆. The putative TATA element in labeled with a box and the two half sites corresponding to the DR1 -like elements are depicted by arrow 1 and arrow 2. B and C, schematic representation of the luciferase reporter gene constructs containing the -165/+47 and the -1588/+47 regions of the human UCP-3 gene and derived mutants with changes in site 1 ( m1) , site 2 ( m2) or both (m1/m2). L6E9 cells were co -transfected with the luciferase reporter gene constructs plus MyoD and RAR α expression vectors. Cells were cultured for 48h and either treated or non-treated for 24h with all-trans RA. The UCP-3 promoter-driven luciferase activity levels were standarized to pRL-CMV-driven Renilla luciferase as transfection internal control. 100% induction was considered as the induction of the -165hUCP3-Luc (B) or -1588hUCP3-Luc (C) elicited by the treatment with all -trans RA. Means ± SE of three independent triplicate experiments are shown as bars. Statistically significant differences are shown as *, p < 0.05. A double-stranded oligonucleotide corresponding to the -79/-57 region of the hUCP3 gene (named as UCP3-DR1) was used as a labeled probe. All the assays were performed in the presence of 5 µg of L6E9 nuclear protein extracts. A, The probe was incubated with L6E9 nuclei extracts and competitors were added at a 100-fold molar excess relative to probe concentration. RARE1 and RARE2 are double-stranded oligonucleotides corresponding to the DR5 RARE from the RARβ gene (27) and to the DR2 RARE from the mouse cellular retinol binding protein type I (28) . ETS is a GA-rich oligonucleotide used as a negative control. B, Effects of RARα, RXRα and ETS antibodies on the formation of DNA-protein complexes between the UCP3-DR1 oligonucleotide and nuclei extracts. 2 µl (2µg/µl) of each antibody were added to the assay as described in Methods section. C, Competition analysis between the UCP3-DR1 and UCP3-DR1m1 (3 base mutation in site 1), UCP3-DR1m2 (3 base mutation in site 2) and UCP3-DR1m3 (3 base mutation outside sites 1 and 2 ) oligonucleotides for the binding with the proteins involved in the formation of the retarded bands A and B (right) and sequence of the UCP3-DR1 oligonucleotide and point-mutation derivatives (UCP3-DR1m1, UCP3-DR1m2 and UCP3-DR1m3) in which the three changed bases are shown in lowercase (left).
